We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+11.25%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$23.8B
AUM Growth
+$2.95B
Cap. Flow
+$1.1B
Cap. Flow %
4.63%
Top 10 Hldgs %
44.66%
Holding
165
New
18
Increased
38
Reduced
31
Closed
20

Top Buys

Rank Stock Value
1
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$3.14B
2
AMZN icon
Amazon
AMZN
+$601M
3
AON icon
Aon
AON
+$226M
4
TMO icon
Thermo Fisher Scientific
TMO
+$145M
5
AZEK
The AZEK Co
AZEK
+$100M

Top Sells

Rank Stock Value
1
DFS
Discover Financial Services
DFS
+$816M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$403M
3
EXEL icon
Exelixis
EXEL
+$260M
4
MSFT icon
Microsoft
MSFT
+$234M
5
INTU icon
Intuit
INTU
+$205M

Sector Composition

Rank Sector Weight
1 Healthcare 32.61%
2 Technology 13.02%
3 Financials 8.98%
4 Communication Services 7.2%
5 Industrials 5.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MARA icon
76
Marathon Digital Holdings
MARA
$3.9B
$13.1M 0.06%
835,000
– –
LTM
77
LATAM Airlines Group S.A.
LTM
$16.3B
$12.9M 0.05%
318,092
-243,918
-43% -$8.44M
GMED icon
78
Globus Medical
GMED
$11.2B
$12.4M 0.05%
210,000
+127,000
+153% +$8.21M
NUVL
79
DELISTED
Nuvalent
NUVL
$11.4M 0.05%
150,000
– –
TYRA icon
80
Tyra Biosciences
TYRA
$1.58B
$10.9M 0.05%
1,143,818
– –
CDTX
81
DELISTED
Cidara Therapeutics
CDTX
$9.74M 0.04%
+200,000
New +$4.81M
BBOT
82
BridgeBio Oncology
BBOT
$747M
$6.39M 0.03%
600,000
– –
LBRDA icon
83
Liberty Broadband Class A
LBRDA
$5.16B
$5.69M 0.02%
58,215
+8,215
+16% +$728K
VYGR icon
84
Voyager Therapeutics
VYGR
$201M
$2.22M 0.01%
715,000
-1,855,700
-72% -$5.99M
PRME icon
85
Prime Medicine
PRME
$559M
$1.85M 0.01%
750,000
– –
ALVO icon
86
Alvotech
ALVO
$1.29B
$1.82M 0.01%
199,675
– –
SMC
87
Summit Midstream
SMC
$419M
$1.43M 0.01%
58,214
– –
JANX icon
88
Janux Therapeutics
JANX
$967M
$1.11M ﹤0.01%
48,000
– –
TVRD
89
Tvardi Therapeutics
TVRD
$23.4M
$1.01M ﹤0.01%
43,225
-3
-0% -$71
MDGL icon
90
Madrigal Pharmaceuticals
MDGL
$11.8B
$1M ﹤0.01%
3,319
– –
BTSG icon
91
BrightSpring Health Services
BTSG
$12.4B
$519K ﹤0.01%
22,000
– –
SLNO
92
DELISTED
Soleno Therapeutics
SLNO
$419K ﹤0.01%
5,000
– –
AXSM icon
93
Axsome Therapeutics
AXSM
$10.9B
$418K ﹤0.01%
4,000
– –
ROIV icon
94
Roivant Sciences
ROIV
$26.2B
$417K ﹤0.01%
37,000
– –
GH icon
95
Guardant Health
GH
$22.6B
$416K ﹤0.01%
+8,000
New +$357K
CAPR icon
96
Capricor Therapeutics
CAPR
$237M
$407K ﹤0.01%
41,000
-2,209,400
-98% -$23.3M
PGNY icon
97
Progyny
PGNY
$2.2B
$396K ﹤0.01%
18,000
– –
SAGE
98
DELISTED
Sage Therapeutics
SAGE
$390K ﹤0.01%
42,800
– –
ARQT icon
99
Arcutis Biotherapeutics
ARQT
$3.18B
$365K ﹤0.01%
26,000
– –
INSM icon
100
Insmed
INSM
$28.6B
$302K ﹤0.01%
3,000
– –
2 3
4
5 6

Similar funds

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Farallon Capital Management held 165 positions worth $23.8B, up 14% from $20.9B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Farallon Capital Management deployed $1.1B of net new capital in Q2 2025, opening 18 new positions and adding to 38 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 5,500,000 shares worth $3.4B.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 38% a quarter earlier, followed by Technology and Financials.

On the sell side, the largest reduction was Exelixis, an estimated $260M trimmed.

  • Farallon Capital Management's largest Q2 2025 buy was State Street SPDR S&P 500 ETF Trust: 5,500,000 shares worth $3.4B.
  • Farallon Capital Management added most to Aon in Q2 2025, an estimated $226M increase.
  • Farallon Capital Management's biggest Q2 2025 reduction was Exelixis, cutting an estimated $260M.
  • Farallon Capital Management fully exited Discover Financial Services in Q2 2025, selling an estimated $816M.
  • Farallon Capital Management's ten largest holdings make up 45% of its $23.8B portfolio in Q2 2025.
  • Farallon Capital Management opened 18 new positions and closed 20 in Q2 2025.
  • Farallon Capital Management's portfolio value rose 14% quarter-over-quarter to $23.8B.

Based on Farallon Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.